Loading...
XNAS
SNOA
Market cap5mUSD
Dec 05, Last price  
3.49USD
1D
-2.24%
1Q
-26.22%
Jan 2017
-99.62%
IPO
-99.99%
Name

Sonoma Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:SNOA chart
P/E
P/S
0.42
EPS
Div Yield, %
Shrs. gr., 5y
-3.42%
Rev. gr., 5y
-5.48%
Revenues
14m
+12.19%
2,584,0004,543,0003,835,0005,388,0007,364,0009,754,00012,744,00015,452,00013,668,00013,854,00015,084,00012,825,00016,658,00018,970,00018,936,00018,629,00012,628,00013,272,00012,735,00014,288,000
Net income
-3m
L-28.50%
-23,099,000-19,783,000-20,339,000-17,656,000-8,232,000-7,948,000-7,329,000-5,431,0003,735,000-8,203,000-10,162,0009,274,000-14,328,000-11,798,000-2,946,000-4,615,000-5,086,000-5,151,000-4,835,000-3,457,000
CFO
-88k
L-96.33%
-20,520,000-18,082,000-17,446,000-16,832,000-6,639,000-4,429,000-4,032,0001,150,000-4,890,000-6,694,000-8,746,000-8,167,000-12,439,000-11,717,000-4,591,000-3,378,000-4,248,000-6,152,000-2,398,000-88,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
IPO date
Jan 26, 2007
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT